Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Pediatr Hematol Oncol
; 38(2): 154-160, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-33150833
ABSTRACT
Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Azacitidina
/
Leucemia Mieloide Aguda
/
Transfusão de Linfócitos
/
Transplante de Células-Tronco Hematopoéticas
/
Condicionamento Pré-Transplante
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Pediatr Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos